Alder, based in a suburb of Seattle, has a monoclonal antibody that it has investigated as a treatment for migraine and is under FDA review, with the agency expected to decide on its approval in February of next year. Shares of Alder were up 83 percent on the news.
The deal struck Thursday follows similar settlements between the Department of Justice and three other drugmakers. The department alleged that the companies started copay-assistance funds that violated anti-kickback laws.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Two years after securing strategic investment from Danish pharmaceutical company Lundbeck, a biopharma startup is collaborating with the company on a drug delivery platform for pain relief and central nervous system disorders. Ossianix’s single domain antibody platform takes its inspiration from a shark model. The first project will advance its antibody platform to treat pain, […]